产品: 磷酸化 p53 (Ser20) 抗体
货号: AF3073
描述: Rabbit polyclonal antibody to Phospho-p53 (Ser20)
应用: WB IHC IF/ICC
文献验证: WB
反应: Human, Mouse, Rat
预测: Pig, Bovine, Sheep, Rabbit, Dog, Xenopus
蛋白号: P04637
RRID: AB_2834510

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1300 现货
 100ul RMB¥ 2400 现货
 200ul RMB¥ 3200 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Phospho-p53 (Ser20) Antibody detects endogenous levels of p53 only when phosphorylated at Serine 20.
RRID:
AB_2834510
引用格式: Affinity Biosciences Cat# AF3073, RRID:AB_2834510.
偶联:
Unconjugated.
纯化:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Antigen NY-CO-13; BCC7; Cellular tumor antigen p53; FLJ92943; LFS1; Mutant tumor protein 53; p53; p53 tumor suppressor; P53_HUMAN; Phosphoprotein p53; Tp53; Transformation related protein 53; TRP53; Tumor protein 53; Tumor protein p53; Tumor suppressor p53;

抗原和靶标

免疫原:

A synthesized peptide derived from human p53 around the phosphorylation site of Ser20.

基因/基因ID:
描述:
Tumor protein p53, a nuclear protein, plays an essential role in the regulation of cell cycle, specifically in the transition from G0 to G1. It is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy.

研究领域

· Cellular Processes > Cell growth and death > Cell cycle.   (View pathway)

· Cellular Processes > Cell growth and death > p53 signaling pathway.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Ferroptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Wnt signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).

· Human Diseases > Neurodegenerative diseases > Huntington's disease.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Thyroid cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Basal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.   (View pathway)

文献引用

1). PTBP1 knockdown promotes neural differentiation of glioblastoma cells through UNC5B receptor. Theranostics, 2022 (PubMed: 35664063) [IF=12.4]

Application: WB    Species: Human    Sample: U251 cells

Figure 7 A DAPK1 inhibitor prevents the PTBP1 knockdown induced reprogramming. (A-E) Western blot study of NTN1, DAPK1, P-DAPK1(Ser308), P-P53(ser20), and caspase 3(p17) protein in U251 cells infected with sh-Luci and sh-PTBP1 for 3 and 7 days. (n = 3). As an internal reference protein, GAPDH was used. (F) Activity of PP2A during reprogramming. (n = 3). (G-I) TUJ1 and KI67 positive rates of six distinct groups constituted of lentivirus (sh-Luci or sh-PTBP1) and TC-DAPK6 (vehicle, 100 nM, 250 nM, and 500 nM; nine random fields from triplicate samples were recorded for quantification; TUJ1+ (%) = TUJ1+ M-cherry+/M-cherry+; KI67+ (%) = KI67+ M-cherry+/M-cherry+; M-cherry+ cells = 156-553 for each condition). The data are presented as mean ± SD. *P < 0.05, *** P < 0.001 vs. sh-Luci-3d or sh-PTBP1 + vehicle group. Dpi (d): days post infection; ND: not detected; NS: no significance. Scale: 100 µm.

2). Metformin attenuates hyperlipidaemia-associated vascular calcification through anti-ferroptotic effects. Free radical biology & medicine, 2021 (PubMed: 33513420) [IF=7.1]

Application: WB    Species: Human    Sample: VSMCs

Fig. 4. The POSTN-enhanced ferroptosis response is p53-dependent in VSMCs. (A) Cells were incubated with rrPOSTN for 0–72 h. The protein expression levels of SLC7A11, phospho-p53 (Ser 20), and p53 were determined by Western blotting. N = 3 independent experiments. (B–C) VSMCs were transfected with NC-shRNA or POSTN-shRNA for 48 h and then exposed to erastin (10 μmol/L) or RSL3 (2.5 μmol/L) for 24 h. Cell viability and iron levels were determined by commercial kits. N = 5 independent experiments. (D) VSMCs were transfected with NC-shRNA or POSTN-shRNA for 48 h, and the protein expression levels of p53 was determined by Western blotting. N = 3 independent experiments. (E)VSMCs were transfected with NC-OE or p53-OE for 48 h, and the protein expression levels of SLC7A11 and Gpx4 were determined by Western blotting. N = 3 independent experiments. (F–G) Cell viability and lipid peroxidation were determined by commercial kits. N = 5 independent experiments. *P < 0.05 and **P < 0.01.

3). AMPK Activity Contributes to G2 Arrest and DNA Damage Decrease via p53/p21 Pathways in Oxidatively Damaged Mouse Zygotes. Frontiers in Cell and Developmental Biology, 2020 (PubMed: 33015052) [IF=4.6]

Application: WB    Species: mouse    Sample: zygotes

FIGURE 5 | Activated AMPK regulates the oxidative stress induction of cell cycle regulatory proteins of p53 and p21 in mouse zygotes. CC, Compound C; SBI, SBI-0206965. (A) Representative data showing the level of p53, p21, p53-pSer15, p53-pSer20 and p53-pSer46 in control, H2O2-treated, Compound C/H2O2-treated, and SBI-0206965/H2O2-treated zygotes in the G2 phase. (B) Quantification data of figure (n = 3). (C) Representative image of the subcellular distribution and expression of p21 (green) using immunostaining. Nuclei were stained with DAPI (blue). Scale bar = 20 µm. (D) Mean fluorescence intensity of nuclear and cytoplasmic p21 in mouse zygotes in the G2 phase. N = 37 zygotes per group. Results in (B,D) were analyzed by one-way ANOVA and Tukey’s test. *p < 0.05; ***p < 0.001. Error bars: SD.

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.